Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis

Effects on bone mineral density

Bruce Carr, W. Paul Dmowski, Chris O'Brien, Ping Jiang, Joshua Burke, Roland Jimenez, Elizabeth Garner, Kristof Chwalisz

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

This randomized double-blind study, with 24-week treatment and 24-week posttreatment periods, evaluated the effects of elagolix (150 mg every day, 75 mg twice a day) versus subcutaneous depot medroxyprogesterone acetate (DMPA-SC) on bone mineral density (BMD), in women with endometriosis-associated pain (n = 252). All treatments induced minimal mean changes from baseline in BMD at week 24 (elagolix 150 mg: -0.11%/-0.47%, elagolix 75 mg: -1.29%/-1.2%, and DMPA-SC: 0.99%/-1.29% in the spine and total hip, respectively), with similar or less changes at week 48 (posttreatment). Elagolix was associated with improvements in endometriosis-associated pain, assessed with composite pelvic signs and symptoms score (CPSSS) and visual analogue scale, including statistical noninferiority to DMPA-SC in dysmenorrhea and nonmenstrual pelvic pain components of the CPSSS. The most common adverse events (AEs) in elagolix groups were headache, nausea, and nasopharyngitis, whereas the most common AEs in the DMPA-SC group were headache, nausea, upper respiratory tract infection, and mood swings. This study showed that similar to DMPA-SC, elagolix treatment had minimal impact on BMD over a 24-week period and demonstrated similar efficacy on endometriosis-associated pain.

Original languageEnglish (US)
Pages (from-to)1341-1351
Number of pages11
JournalReproductive Sciences
Volume21
Issue number11
DOIs
StatePublished - Nov 12 2014

Fingerprint

Medroxyprogesterone Acetate
Endometriosis
Gonadotropin-Releasing Hormone
Bone Density
Pain
Nausea
Signs and Symptoms
Headache
Nasopharyngitis
Therapeutics
Dysmenorrhea
Pelvic Pain
Visual Analog Scale
Double-Blind Method
Respiratory Tract Infections
elagolix
Hip
Spine
N,N-dimethyl-4-anisidine

Keywords

  • Elagolix
  • Endometriosis
  • GnRH antagonists
  • Pelvic pain

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis : Effects on bone mineral density. / Carr, Bruce; Dmowski, W. Paul; O'Brien, Chris; Jiang, Ping; Burke, Joshua; Jimenez, Roland; Garner, Elizabeth; Chwalisz, Kristof.

In: Reproductive Sciences, Vol. 21, No. 11, 12.11.2014, p. 1341-1351.

Research output: Contribution to journalArticle

Carr, Bruce ; Dmowski, W. Paul ; O'Brien, Chris ; Jiang, Ping ; Burke, Joshua ; Jimenez, Roland ; Garner, Elizabeth ; Chwalisz, Kristof. / Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis : Effects on bone mineral density. In: Reproductive Sciences. 2014 ; Vol. 21, No. 11. pp. 1341-1351.
@article{b307347eef0b41d2bf7748d40b009f9a,
title = "Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: Effects on bone mineral density",
abstract = "This randomized double-blind study, with 24-week treatment and 24-week posttreatment periods, evaluated the effects of elagolix (150 mg every day, 75 mg twice a day) versus subcutaneous depot medroxyprogesterone acetate (DMPA-SC) on bone mineral density (BMD), in women with endometriosis-associated pain (n = 252). All treatments induced minimal mean changes from baseline in BMD at week 24 (elagolix 150 mg: -0.11{\%}/-0.47{\%}, elagolix 75 mg: -1.29{\%}/-1.2{\%}, and DMPA-SC: 0.99{\%}/-1.29{\%} in the spine and total hip, respectively), with similar or less changes at week 48 (posttreatment). Elagolix was associated with improvements in endometriosis-associated pain, assessed with composite pelvic signs and symptoms score (CPSSS) and visual analogue scale, including statistical noninferiority to DMPA-SC in dysmenorrhea and nonmenstrual pelvic pain components of the CPSSS. The most common adverse events (AEs) in elagolix groups were headache, nausea, and nasopharyngitis, whereas the most common AEs in the DMPA-SC group were headache, nausea, upper respiratory tract infection, and mood swings. This study showed that similar to DMPA-SC, elagolix treatment had minimal impact on BMD over a 24-week period and demonstrated similar efficacy on endometriosis-associated pain.",
keywords = "Elagolix, Endometriosis, GnRH antagonists, Pelvic pain",
author = "Bruce Carr and Dmowski, {W. Paul} and Chris O'Brien and Ping Jiang and Joshua Burke and Roland Jimenez and Elizabeth Garner and Kristof Chwalisz",
year = "2014",
month = "11",
day = "12",
doi = "10.1177/1933719114549848",
language = "English (US)",
volume = "21",
pages = "1341--1351",
journal = "Reproductive Sciences",
issn = "1933-7191",
publisher = "SAGE Publications Inc.",
number = "11",

}

TY - JOUR

T1 - Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis

T2 - Effects on bone mineral density

AU - Carr, Bruce

AU - Dmowski, W. Paul

AU - O'Brien, Chris

AU - Jiang, Ping

AU - Burke, Joshua

AU - Jimenez, Roland

AU - Garner, Elizabeth

AU - Chwalisz, Kristof

PY - 2014/11/12

Y1 - 2014/11/12

N2 - This randomized double-blind study, with 24-week treatment and 24-week posttreatment periods, evaluated the effects of elagolix (150 mg every day, 75 mg twice a day) versus subcutaneous depot medroxyprogesterone acetate (DMPA-SC) on bone mineral density (BMD), in women with endometriosis-associated pain (n = 252). All treatments induced minimal mean changes from baseline in BMD at week 24 (elagolix 150 mg: -0.11%/-0.47%, elagolix 75 mg: -1.29%/-1.2%, and DMPA-SC: 0.99%/-1.29% in the spine and total hip, respectively), with similar or less changes at week 48 (posttreatment). Elagolix was associated with improvements in endometriosis-associated pain, assessed with composite pelvic signs and symptoms score (CPSSS) and visual analogue scale, including statistical noninferiority to DMPA-SC in dysmenorrhea and nonmenstrual pelvic pain components of the CPSSS. The most common adverse events (AEs) in elagolix groups were headache, nausea, and nasopharyngitis, whereas the most common AEs in the DMPA-SC group were headache, nausea, upper respiratory tract infection, and mood swings. This study showed that similar to DMPA-SC, elagolix treatment had minimal impact on BMD over a 24-week period and demonstrated similar efficacy on endometriosis-associated pain.

AB - This randomized double-blind study, with 24-week treatment and 24-week posttreatment periods, evaluated the effects of elagolix (150 mg every day, 75 mg twice a day) versus subcutaneous depot medroxyprogesterone acetate (DMPA-SC) on bone mineral density (BMD), in women with endometriosis-associated pain (n = 252). All treatments induced minimal mean changes from baseline in BMD at week 24 (elagolix 150 mg: -0.11%/-0.47%, elagolix 75 mg: -1.29%/-1.2%, and DMPA-SC: 0.99%/-1.29% in the spine and total hip, respectively), with similar or less changes at week 48 (posttreatment). Elagolix was associated with improvements in endometriosis-associated pain, assessed with composite pelvic signs and symptoms score (CPSSS) and visual analogue scale, including statistical noninferiority to DMPA-SC in dysmenorrhea and nonmenstrual pelvic pain components of the CPSSS. The most common adverse events (AEs) in elagolix groups were headache, nausea, and nasopharyngitis, whereas the most common AEs in the DMPA-SC group were headache, nausea, upper respiratory tract infection, and mood swings. This study showed that similar to DMPA-SC, elagolix treatment had minimal impact on BMD over a 24-week period and demonstrated similar efficacy on endometriosis-associated pain.

KW - Elagolix

KW - Endometriosis

KW - GnRH antagonists

KW - Pelvic pain

UR - http://www.scopus.com/inward/record.url?scp=84909589792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84909589792&partnerID=8YFLogxK

U2 - 10.1177/1933719114549848

DO - 10.1177/1933719114549848

M3 - Article

VL - 21

SP - 1341

EP - 1351

JO - Reproductive Sciences

JF - Reproductive Sciences

SN - 1933-7191

IS - 11

ER -